Comparison between Allopurinol and Febuxostat in management of gout patients - A prospective study

Bangladesh Journal of Medical Science

Volumn 10, Issue 4, 2011, Pages 257-259

  Singal, K K ^a   Goyal, S ^a   Gupta, P ^a   Aggawal, B K ^a  

^a MAHARISHI MARKANDESHWAR INSTITUTE OF MEDICAL SCIENCES AND RESEARCH   (India)

Author keywords

Allopurinol; Febuxostat; Gout; Uric acid

Indexed keywords

ALLOPURINOL; FEBUXOSTAT; URIC ACID;

ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; GOUT; HEADACHE; HUMAN; HYPERSENSITIVITY REACTION; HYPERURICEMIA; LIVER FUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROSPECTIVE STUDY; RASH; SIDE EFFECT; URIC ACID BLOOD LEVEL;

EID: 84856489267     PISSN: 22234721     EISSN: 20760299     Source Type: Journal    
DOI: 10.3329/bjms.v10i4.7522     Document Type: Article

References (13)

1. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14: 281-286. http://dx.doi.org/10.1097/00002281-200205000-00015. PMid:11981327.
2. Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyper-uricemic therapy. Arthritis Rheum 2004; 51: 321-325. http://dx.doi.org/10.1002/art.20405.
3. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G, Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57: 545-549. http://dx.doi.org/10.1136/ard.57.9.545. PMid:9849314. PMCid:1752740.
4. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004; 64: 2399-2416. http://dx.doi.org/10.2165/00003495-200464210-00003. PMid:15481999.
5. Harris MD, Siegel LB, Alloway JA. Gout and hyper-uricemia. Am Fam Physician 1999; 59: 925-934. PMid:10068714.
6. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003; 278: 1848-1855. http://dx.doi.org/10.1074/jbc.M208307200. PMid:12421831.
7. Becker MA, Kisicki J, Khosraven R, et al. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1111-1116. http://dx.doi.org/10.1081/NCN-200027372. PMid:15571211.
8. Hoshide S, Nishimura S, Ishii S, Matsuzawa K, Saito N, Tanaka T. Metabolites of TMX-67, a new pharmaceutical entity for the treatment of gout or hyper-uricemia, and their pharmacokinetic profiles in humans. Drug Metab Rev 2000; 32: (2): 269-269.
9. Khosravan R, Mayer M, Grabowski B, Vernillet L, Wu J-T, Joseph-Ridge N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase effect of mild and moderate hepatic impairment on pharma-cokinetics, pharmacodynamics, and safety. Arthritis Rheum 2004; 50: S337-S337 abstract.
10. Khosravan R, Mayer M, Grabowski B, Vernillet L, Wu J-T, Joseph-Ridge N. Febuxostat, a novel non-purine selective inhibitor of xanthine oxidase e fect of mild and moderate hepatic impairment on pharma-cokinetics, pharmacodynamics, and safety. Arthritis Rheum 2004; 50: S337-S337 abstract.
11. Perez-Ruiz F, Calabozo M, Pijoan J, Herrero-Beites AM, Ruibal A. Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-360. http://dx.doi.org/10.1002/art.10511.
12. Brewis I, Ellis RM, Scott JT. Single daily dose of allopurinol. Ann Rheum Dis 1975; 34: 256-259. http://dx.doi.org/10.1136/ard.34.3.256. PMid:1098582. PMCid:1006407.
13. Yamanaka H, Togashi R, Hakoda M, et al. Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment. Adv Exp Med Biol 1998; 431: 13-18. http://dx.doi.org/10.1007/978-1-4615-5381-6_3.